AVADEL PHARMACEUTICALS PLC (AVDL) — Institutional Holders, Q2 2026
1 institutional investment managers reported a AVDL position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $16.00. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
AVDL in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
None this quarter.
Biggest sellers
- IFP AdvisorsSold out · -20 sh-$320.00
AVDL 13F holders ranked 1–1 of 1
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | HUNTINGTON NATIONAL BANK#1 · 1 sh | 1 | $16.00 | 0.00% | 0.0% |
Funds that sold out of AVDL in Q2 2026 (1)
Held AVDL at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| IFP Advisors20 sh | 20 | $426.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.